–News Direct– Strip Tinning Holdings PLC (AIM:STG) executive chairman Adam Robson joined Proactive's Stephen Gunnion with an overview of the company and highlights of its 2023 financial year. Founded in…
–News Direct– Giyani Metals Corp (TSX-V:EMM, OTC:CATPF) CEO Danny Keating joined Proactive's Stephen Gunnion with news that the company is pushing quickly ahead with its flagship high-purity K. Hill manganese…
–News Direct– New York, May 1st, 2024 – (PlatoAI via 500NewsWire) — In a world often colored by political machinations and self-serving motivations, Representative Wilbert T. Lee emerges as a…
–News Direct– Sovereign Metals Limited managing director Frank Eagar joins Proactive's Stephen Gunnion with details of key developments. The company has appointed Dr Surinder Ghag as chief technology officer for…
–News Direct– Genius Group Limited (NYSE-A:GNS) CEO Roger Hamilton discusses the company's innovative use of artificial intelligence (AI) in education with Proactive's Stephen Gunnion. Genius Group, an edtech firm, is…
–News Direct– Rainbow Rare Earths Ltd CEO George Bennett joins Proactive's Stephen Gunnion with details of a Financial Times feature that highlighted the company's Phalaborwa rare earths project as a…
–News Direct– ETC Group founder and chief strategy officer Bradley Duke discusses recent trends in Bitcoin's market performance and future expectations with Proactive's Stephen Gunnion. He noted Bitcoin's peak prices…
–News Direct– Argent BioPharma managing director and CEO Roby Zomer speaks to Proactive's Stephen Gunnion following the company's rebranding from MGC Pharmaceuticals, alongside a comprehensive restructuring. Zomer explained the shift…
–News Direct– Nexus Minerals Ltd managing director Andy Tudor joined Proactive's Stephen Gunnion with details of a significant expansion of the Crusader Templar resource at the Wallbrook gold project, which…
–News Direct– Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium…